Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia

Anderson, Keith; Chambers, Carole; Lam, Nadine; Yau, Patrick; Cusano, Frances; Savoie, Mary Lynn; Sheikh, Naureen

doi:10.1177/1078155213520261

Cited by 39 publications

(46 citation statements)

References 21 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are several methods for measuring adherence to a treatment, but none is substantially free of limitations. If the patient is aware that adherence is being evaluated, this can influence the result from the self-reporting method, in which the patient is invited to report how faithfully the prescribed regime was followed (2,5) . Another method is to count the pills.…”

Section: Study On Adherence To Capecitabine Among Patients With Colormentioning

confidence: 99%

Study on Adherence to Capecitabine Among Patients With Colorectal Cancer and Metastatic Breast Cancer

Figueiredo

Forones

2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Capecitabine, an oral drug, is as effective as traditional chemotherapy drugs. Objectives -To investigate the adhesion to treatment with oral capecitabine in breast and colorectal cancer, and to determine any correlation with changes in patient's quality of life. Methods -Patients with colorectal cancer or breast cancer using capecitabine were included. The patients were asked to bring any medication left at the time of scheduled visits. The QLQ-C30 questionnaire was applied at the first visit and 8-12 weeks after treatment. Results -Thirty patients were evaluated. Adherence was 88.3% for metastatic colon cancer, 90.4% for non-metastatic colon cancer, 94.3% for rectal cancer and 96.2% for metastatic breast cancer. No strong correlation between adherence and European Organisation for Research and Treatment of Cancer QLQ-C30 functional or symptom scale rates had been found. There was no statistically significant correlation between compliance and the functional and symptom scales of the questionnaire before and after chemotherapy, with the exception of dyspnea. Conclusion -Although no absolute adherence to oral capecitabine treatment had been observed, the level of adherence was good. Health professionals therefore need a greater focus in the monitoring the involvement of patients with oral treatment regimens. Patients with lesser degrees of dyspnea had greater compliance.

show abstract

Section: Study On Adherence To Capecitabine Among Patients With Colormentioning

confidence: 99%

Study on Adherence to Capecitabine Among Patients With Colorectal Cancer and Metastatic Breast Cancer

Figueiredo

Forones

2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…'the extent of conformity to the recommendations about day to day treatment by the provider with respect to timing, dosage and frequency' [3] is crucial to achieve optimal treatment response [6][7][8]11,12,17,[26][27][28][29][30][31]32]. Yet the fact that CML has become a manageable chronic disease with much improved quality of life (QoL) may challenge adherence [4,8,26].…”

mentioning

confidence: 99%

“…nd generation TKIs dasatinib, nilotinib, and bosutinib have since been approved [7], followed by 3 rd generation ponatinib [4,8,9]. Some patients are initially treated with hydroxyurea [4].…”

mentioning

confidence: 99%

“…Non-adherence in up to 25-30% of CML patients have been suggested [4,7,19,[26][27][28]30,33]. Side effects are the most frequent reason for intentional non-adherence and has been associated with a negative impact on activities such as travels, other illness, psycho-social well-being and QoL [3,4,6,7,[9][10][11][13][14][15]17,26,29,31,33,34].…”

mentioning

confidence: 99%

“…As CML is a lowgrade symptom disease, treatment often represents patients' main disease impact [3,10]. Side effects are mostly considered mild to moderate but may include edema, diarrhoea, pleural effusions, nausea, muscosceletal or abdominal pain, rashes, fatigue, or headache [1][2][3][4]7,9,[11][12][13][14][15][16][17][18][19][20][21].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Mortensen¹,

Mourek

2017

JHOR

View full text Add to dashboard Cite

With the introduction of tyrosine kinase inhibitors (TKI), patients with chronic myeloid leukemia (CML) have obtained survival rates close to normal. It may appear paradoxical, then, that medication adherence is suboptimal in some health care settings. As the first of its kind, this study aimed to explore drivers and barriers to TKI treatment adherence in Danish CML patients. A literature study informed the design of qualitative interviews with 20 patients, individually and in focus groups, focusing on their disease perceptions of CML, their health-related quality of life (QoL) and medication adherence. The study showed that many participants had previously switched treatment due to lacking efficacy or intolerance but most felt their current disease burden was tolerable. Anxiety might, however, resurface if treatment stopped working or with the occurrence of infections or side effects, creating a state of 'fragile peace'. To these patients, their role functioning -as professionals, spouses, parents and grandparents -was crucial to uphold a positive self-image and meaningful life. Whether treatment enabled or hindered this was thus decisive to their QoL and medication adherence. Our participants expressed high adherence rates with only one having intentionally non-adhered due to side effects and poor QoL. Most participants felt well-informed about CML and treatment and privileged to receive specialised personal care from the public health care system acting to motivate their medication adherence. As a novel finding, this study indicates that the prospect of treatment-free remission may positively affect adherence. We suggest this should be explored in future studies.

show abstract

Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer

et al. 2022

View full text Add to dashboard Cite

ImportanceThe phosphoinositide 3-kinase (PI3K) pathway is among the most frequently activated pathways in human cancers. As the use of PI3K inhibitors for cancer treatment grows, there is increasing need for understanding the cutaneous effects associated with these therapies.ObjectiveTo systematically review the published literature reporting incidence of cutaneous adverse events with PI3K inhibitors and to provide pooled incidence estimates using meta-analysis.Data SourcesThis systematic review and meta-analysis was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. The literature search concerned entries through September 2021 in the following sources: PubMed, Cochrane registry, ClinicalTrials.gov, and evidence from the NHS UK and Trip medical database. To analyze PI3K inhibitors’ cutaneous adverse events incidence, only randomized clinical trials (RCTs) were considered. The search strategy used the following keywords: (prevalence OR incidence OR epidemiology) and (phosphoinositide 3 kinase inhibitors OR PI3K inhibitors). No language restriction was applied. Analysis was conducted on July 1, 2022.Study SelectionStudies included phase 2 and phase 3 RCTs that reported incidence of cutaneous adverse events associated with use of PI3K inhibitors.Data Extraction and MeasuresData extracted included sex, medication name and class, sample size, rash incidence, and grade. The bias risk was assessed by the Cochrane tool for risk of bias assessment in RCTs.Main Outcomes and MeasuresThe primary outcome was incidence of PI3K inhibitor cutaneous adverse events (with 95% CIs) among the overall population and among subgroups. Between-study heterogeneity was assessed using the I2 statistic.ResultsThe analysis found the incidence of PI3K inhibitor cutaneous events of any grade to be 29.30% in the intervention group, translating to a pooled odds ratio (OR) for incidence of cutaneous adverse events of any grades of 2.55 (95% CI, 1.74-3.75). Incidence of severe grade (grade ≥3) of rash in the intervention group was estimated to be 6.95%, yielding a pooled Peto OR of 4.64 (95% CI, 2.70-7.97). Subgroup analyses revealed that the incidence of severe cutaneous adverse events (grade ≥3) was higher with the use of Pan-class-1 PI3K inhibitors (OR, 6.67; 95% CI, 4.28-10.38) than isoform-selective PI3K inhibitors (OR, 6.37; 95% CI, 3.25-12.48).Conclusions and RelevanceThis systematic review and meta-analysis identified an overall incidence of PI3K inhibitor cutaneous adverse events of any grade to be 29.30% with a pooled OR of 2.55; (95% CI, 1.74-3.75). These findings clarify the risk of cutaneous adverse events associated with this important class of anticancer therapies.

show abstract

Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia

Cited by 39 publications

References 21 publications

Study on Adherence to Capecitabine Among Patients With Colorectal Cancer and Metastatic Breast Cancer

Study on Adherence to Capecitabine Among Patients With Colorectal Cancer and Metastatic Breast Cancer

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer

Contact Info

Product

Resources

About